Arthur Marie Joseph Ghislain Deboeck, a Director, acquired 72,200 Common Shares on a direct ownership basis at prices ranging from US$0.937 to US$0.955 between August 19th and 22nd, 2019. The insider also acquired 67,300 Common Shares on a direct ownership basis at prices ranging from $1.184 to $1.197 between August 15th and 16th, 2019. This represents a $170,644 investment into the company's shares and an account share holdings change of greater than 100%.
Cipher Pharmaceuticals is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.
No Comments